Biomerica (BMRA) vs Celldex Therapeutics (CLDX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Celldex Therapeutics (CLDX) has outperformed Biomerica (BMRA) over the past year, gaining 16.1% versus a loss of 32.7%. Over five years, CLDX leads with a -34.1% price change compared with -95.7% for BMRA. Celldex Therapeutics is the larger company by market cap ($2.39 billion vs $8.8 million), about 272.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BMRA | CLDX |
|---|---|---|
| Share price | $1.91 | $30.43 |
| Market cap | $8.78M | $2.39B |
| 1-day change | -10.75% | -1.85% |
| YTD return | -24.21% | +12.04% |
| 1-year return | -32.75% | +16.06% |
| 5-year return | -95.69% | -34.11% |
| Forward P/E | 4.90 | — |
| EPS (TTM) | $-1.30 | $-4.35 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $1.54M |
| Revenue growth (YoY) | — | -77.99% |
| Net income (latest FY) | — | $-258.76M |
| Gross margin | — | 87.06% |
| Operating margin | — | -18599.81% |
| Net margin | — | -16748.03% |
| 52-week high | $3.21 | $45.14 |
| 52-week low | $1.45 | $22.10 |
| Distance from 52-week high | -40.50% | -32.59% |
| Analyst consensus | — | strong_buy |
| Avg. price target upside | — | +107.26% |
| Average volume | 70.89K | 1.27M |
| Shares outstanding | 4.60M | 78.53M |
| Employees | — | 198 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Celldex Therapeutics is about 272.0 times larger than Biomerica by market value ($2.39B vs $8.78M).
- CLDX has outperformed BMRA by 48.8 percentage points over the past year.
About Celldex Therapeutics
CLDX stock →Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company's drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 198 employees
BMRA vs CLDX FAQ
Which is bigger, Biomerica or Celldex Therapeutics?
Celldex Therapeutics (CLDX) is larger, with a market capitalization of $2.39B compared with $8.78M for Biomerica (BMRA).
Which stock has performed better over the past year, BMRA or CLDX?
CLDX returned +16.06% over the past 12 months, compared with -32.75% for BMRA (price return, excluding dividends). Past performance does not predict future results.
Are Biomerica and Celldex Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: In Vitro & In Vivo Diagnostic Substances industry within the Health Care sector.